Lava Therapeutics NV 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
LAVA Therapeutics, a clinical-stage immuno-oncology company, files its 20-F report, detailing its financial results for the year ended December 31, 2023, and providing an overview of its operations and key developments.